Prosecutors Raid Hanmi HQ As Olmutinib Probe Gets Serious
Executive Summary
Following the start of a probe by financial authorities earlier this month into suspicions Hanmi may have leaked undisclosed information relating to the return of rights to its cancer drug olmutinib, prosecutors have raided the headquarters of the South Korean pharma to get to the bottom of the affair.
You may also be interested in...
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Korean Authorities Mull New Steps, Probe Over Olmutinib Events
Additional safety measures including a possible sales suspension are to be discussed by a review committee in South Korea on Oct. 4 that will help decide the fate of Hanmi’s EGFR inhibitor olmutinib. Financial authorities in the country are also launching a probe into the timing of the disclosure of several cases of serious adverse events with the drug.